gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Vasoactive intestinal peptide receptor 2

VPAC2, VIPR2, VPAC2 receptor
This gene encodes a receptor for vasoactive intestinal peptide, a small neuropeptide. Vasoactive intestinal peptide is involved in smooth muscle relaxation, exocrine and endocrine secretion, and water and ion flux in lung and intestinal epithelia. Its actions are effected through integral membrane receptors associated with a guanine nucleotide binding protein which activates adenylate cyclase. [provided by RefSeq, Aug 2011] (from NCBI)
Top mentioned proteins: Vasoactive Intestinal Peptide, VPAC1, PACAP, Neuropeptide, V1a
Papers on VPAC2
Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Jensen et al., Bethesda, United States. In Curr Opin Endocrinol Diabetes Obes, Feb 2016
PURPOSE OF REVIEW: To summarize the roles of vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating polypeptide (PACAP) and their receptors (VPAC1, VPAC2, PAC1) in human tumors as well as their role in potential novel treatments.
Genetic blockade of the dopamine D3 receptor enhances hippocampal expression of PACAP and receptors and alters their cortical distribution.
Castorina et al., Catania, Italy. In Neuroscience, Jan 2016
Consistently, PAC1, VPAC1 and VPAC2 IRs were variably redistributed in CX, with a general upregulation in cortical layers II-IV in knockout animals.
Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.
Gendelman et al., Omaha, United States. In J Neurosci, Jan 2016
UNLABELLED: Vasoactive intestinal peptide (VIP) mediates a broad range of biological responses by activating two related receptors, VIP receptor 1 and 2 (VIPR1 and VIPR2).
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.
Ramhorst et al., Buenos Aires, Argentina. In Sci Rep, Dec 2015
Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/J × DBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice.
Identification of genomic biomarkers associated with the clinicopathological parameters and prognosis of esophageal squamous cell carcinoma.
Hao et al., Kunming, China. In Cancer Biomark, Dec 2015
and MRPL21 (11q13.2) as well as decrease of VIPR2 (7q36.3)
Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine.
Goadsby et al., San Francisco, United States. In Sci Transl Med, Nov 2015
Both VIP and PACAP-38 caused short-lived meningeal vasodilation mediated by VPAC2 receptors, which did not coincide with activation of central trigeminovascular neurons.
Therapeutic potential of PACAP for neurodegenerative diseases.
Xin et al., In Cell Mol Biol Lett, Jun 2015
PACAP can initiate multiple signaling pathways through binding with three class B G-protein coupled receptors, PAC1, VPAC1 and VPAC2.
Rhythmic control of activity and sleep by class B1 GPCRs.
Nitabach et al., New Haven, United States. In Crit Rev Biochem Mol Biol, 2015
This review discusses the cellular and molecular mechanisms by which class B1 GPCRs, especially the mammalian VPAC2 receptor and its functional homologue PDFR in Drosophila and C. elegans, regulate arousal and daily rhythms of sleep and wake.
Advent and recent advances in research on the role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the regulation of gonadotropic hormone secretion of female rats.
Szabó et al., Budapest, Hungary. In J Mol Neurosci, 2014
PACAP activates three distinct receptor types: G-protein coupled PAC1, VPAC1, and VPAC2 with seven transmembrane domains.
Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases.
Seo et al., Ch'unch'ŏn, South Korea. In Bmb Rep, 2014
PACAP is widely distributed in the central and peripheral nervous systems and acts as a neurotransmitter, neuromodulator, and neurotrophic factor via three major receptors (PAC1, VPAC1, and VPAC2).
[Intercellular communication-based robust circadian oscillation of the suprachiasmatic nucleus in the brain: mechanisms beyond intracellular clock machinery].
Doi, Kyoto, Japan. In Nihon Rinsho, 2013
Inactivation of the genes involved in the cell-cell synchronization of the SCN, which include the genes encoding VIP, VPAC2, and RGS16, leads to altered circadian rhythms in behavior and physiologies.
Type 2 innate lymphoid cells control eosinophil homeostasis.
Locksley et al., San Francisco, United States. In Nature, 2013
The circadian synchronizer vasoactive intestinal peptide also stimulates ILC2 cells through the VPAC2 receptor to release IL-5, linking eosinophil levels with metabolic cycling.
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Sánchez-Chapado et al., Alcalá de Henares, Spain. In Histol Histopathol, 2012
The overexpression of VPAC1 and VPAC2 receptors and COX-2 in cancer tissue gives them a potential role as targets for diagnosis of prostate cancer.
Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.
Leirós et al., Buenos Aires, Argentina. In Clin Exp Immunol, 2011
results support that decline in VIP/VPAC local levels may influence survival/apoptosis intracellular set point in NOD acinar cells and their clearance, contributing to gland homeostasis loss in a model of Sjogren's syndrome
Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
Halmos et al., Debrecen, Hungary. In Int J Oncol, 2011
mRNA expression of the VPAC1 receptor was detected in 51% of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46%.
Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
Dorsam et al., Fargo, United States. In Peptides, 2011
Data support the notion that both VPAC1 and VPAC2 receptors are dynamically regulated by Ikaros, a master transcriptional regulator for thymocyte differentiation, during early thymic development.
Genome-wide investigation of rare structural variants identifies VIPR2 as a new candidate gene for schizophrenia.
Witt et al., Mannheim, Germany. In Expert Rev Neurother, 2011
gene expression level and cAMP signaling of VIPR2 were increased in patients carrying 7q36.3 microduplications, thus implicating VIPR2 in the etiology of schizophrenia.[review]
Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia.
Sebat et al., New York City, United States. In Nature, 2011
These findings implicate altered vasoactive intestinal peptide signalling in the pathogenesis of schizophrenia and indicate the VPAC2 receptor as a potential target for the development of new antipsychotic drugs.
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.
Vaudry et al., Mont-Saint-Aignan, France. In Pharmacol Rev, 2009
Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes: the PACAP-specific PAC1-R, which is coupled to several transduction systems, and the PACAP/VIP-indifferent VPAC1-R and VPAC2-R, which are primarily coupled to adenylyl cyclase.
Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
Vaudry et al., Mont-Saint-Aignan, France. In Pharmacol Rev, 2000
Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes, the PACAP-specific PAC1 receptor, which is coupled to several transduction systems, and the two PACAP/VIP-indifferent VPAC1 and VPAC2 receptors, which are primarily coupled to adenylyl cyclase.
share on facebooktweetadd +1mail to friends